Neil Kumar - Nov 19, 2024 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Signature
/s/ Brian C. Stephenson, Attorney-in-Fact
Stock symbol
BBIO
Transactions as of
Nov 19, 2024
Transactions value $
-$613,826
Form type
4
Date filed
11/20/2024, 08:00 PM
Previous filing
Nov 19, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BBIO Common Stock Sale -$571K -25.5K -0.52% $22.39 4.9M Nov 19, 2024 Direct F1, F2
transaction BBIO Common Stock Sale -$42.7K -1.88K -0.04% $22.76 4.9M Nov 19, 2024 Direct F1, F3
holding BBIO Common Stock 1.01M Nov 19, 2024 By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. F4
holding BBIO Common Stock 996K Nov 19, 2024 By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024.
F2 Represents the weighted average sale price of the shares sold ranging from $21.73 to $22.72 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F3 Represents the weighted average sale price of the shares sold ranging from $22.73 to $22.92 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F4 The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.